• Publications
  • Influence
Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients
ABSTRACT With increasing clinical emergence of multidrug-resistant Gram-negative pathogens and the paucity of new agents to combat these infections, colistin (administered as its inactive prodrugExpand
  • 561
  • 45
  • PDF
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.
Increasing multidrug resistance in Gram-negative bacteria, in particular Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae, presents a critical problem. Limited therapeuticExpand
  • 1,014
  • 37
  • PDF
Colistin Resistance in Acinetobacter baumannii Is Mediated by Complete Loss of Lipopolysaccharide Production
ABSTRACT Infections caused by multidrug-resistant (MDR) Gram-negative bacteria represent a major global health problem. Polymyxin antibiotics such as colistin have resurfaced as effective last-resortExpand
  • 485
  • 37
  • PDF
Structure--activity relationships of polymyxin antibiotics.
Tony Velkov,* Philip E. Thompson, Roger L. Nation, and Jian Li* School of Medicine, Deakin University, Pigdons Road, Geelong 3217, Victoria, Australia, Medicinal Chemistry and Drug Action andExpand
  • 392
  • 24
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.
Polymyxins have re-emerged in clinical practice owing to the dry antibiotic development pipeline and worldwide increasing prevalence of nosocomial infections caused by multidrug-resistant (MDR)Expand
  • 552
  • 22
  • PDF
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
Infections caused by multi-resistant Gram-negative bacteria, particularly Pseudomonas aeruginosa, are increasing worldwide. In patients with cystic fibrosis (CF), resistance in P. aeruginosa toExpand
  • 460
  • 20
Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.
BACKGROUND Polymyxin B is a last-line therapy for multidrug-resistant gram-negative bacteria. There is a dearth of pharmacokinetic data to guide dosing in critically ill patients. METHODSExpand
  • 232
  • 20
  • PDF
Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii
ABSTRACT Multidrug-resistant Acinetobacter baumannii has emerged as a significant clinical problem worldwide and colistin is being used increasingly as “salvage” therapy. MICs of colistin against A.Expand
  • 474
  • 17
  • PDF
Colistin and polymyxin B: peas in a pod, or chalk and cheese?
Colistin and polymyxin B have indistinguishable microbiological activity in vitro, but they differ in the form administered parenterally to patients. Polymyxin B is administered directly as theExpand
  • 165
  • 17
  • PDF
Management of meningitis due to antibiotic-resistant Acinetobacter species.
Acinetobacter meningitis is becoming an increasingly common clinical entity, especially in the postneurosurgical setting, with mortality from this infection exceeding 15%. Infectious Diseases SocietyExpand
  • 170
  • 14
  • PDF